Cyfra 21-1 in diagnosis of distant metastases of head and neck carcinoma

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 917-920

  Hoffmann Fazel, Asita ^a   Hoffmann, Markus ^a   Gottschlich, Stefan ^a   Maass, Jan D ^a   Rudert, Heinrich ^a   Maune, Steffen ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Cyfra 21 1; Distant metastases; HNSSC; Recurrences; Tumor marker

Indexed keywords

CYTOKERATIN 19 FRAGMENT;

ACCURACY; ADULT; AGED; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR RECURRENCE;

AGED; ANTIGENS, NEOPLASM; CARCINOMA, BRONCHOGENIC; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; FALSE POSITIVE REACTIONS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KERATINS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS;

EID: 0037524335     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Bodenmüller H, Banauch D, Ofenloch B, Jaworek, D and Dessauer A: Technical evaluation of a new automated tumor marker assay: The Enzymun-Test Cyfra 21-1. In: Klapdor R (Ed.) Tumor Associated Antigens, Oncogenes, Receptors, Cytokines in Tumor Diagnosis and Therapy at the Beginning of the Nineties. Munich: Zuckschwerdt: 137-138, 1992.
2. Cooper D, Schermer A and Sun T-T: Biology of disease. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations. Lab Invest 52: 243-256, 1985.
3. Broers JLV, Ramaekers FCS, Rot MK, Oostendorp T, Huysmans A, van Muijen GNP, Wagenaar SS and Vooijs GP: Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 48: 3221-3229, 1988.
4. Stieber P, Müller C, Hasholzner U, Dienemann H, Fiebig M and Fateh-Moghadam A: Cyfra 21-1- ein neuer Marker beim Bronchialkarzinom. Lab Med 17: 328-332, 1993.
5. Van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Cornillie F and Splinter TAW: Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21-1. Br J Cancer 69: 525-528, 1994.
6. Niemann AM, Broers H, Görögh T, Gottschlich S, Maune S, Lippert BM and Werner JA: Serum fragment of cytokeratin 19 as a marker of squamous cell carcinomas of the head and neck. J Tumor Marker Oncol 10: 70-71, 1995.
7. Hoefliger M, Morant R, Riesen W, Baumgartner G and Engler H: Cyfra 21-1: initial experiences in bronchus carcinoma and other tumors. Schweiz Med Wochenschr 124: 1966-1970, 1994.
8. Koga H, Eguchi, K, Shinkai T, Tamura T, Ohe Y, Oshita F, Saijo N, Kondo H, Oki K and Okura H: Preliminary evaluation of the new tumor marker, Cyfra 21-1, in lung cancer patients. Jpn J Clin Oncol 24: 263-268, 1994.
9. Sugama Y, Kitamura S, Kawai T, Ohkubo A, Hasegawa S, Kuriyama T, Kato H, Fukuoka M and Ohkawa J: Clinical usefulness of Cyfra assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res 85: 1178-1184, 1994.
10. Yamamoto K, Oka M, Hayashi H,.Tangoku A, Gondo T and Suzuki T: Cyfra 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 79: 1647-1655, 1997.
11. Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatov M and Laufer D: Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 85: 1018-1025, 1999.
12. Niemann AM, Görögh T, Gottschlich S, Lippert BM and Werner JA: Cut-off value determination of Cyfra 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Anticancer Res 17: 2859-2860, 1997.
13. Goumas PD, Mastronikolis NS, Mastorakou AN, Vassilakos PJ and Nikiforidis GC: Evaluation of TATI and Cyfra 21-1 in patients with head and neck squamous cell carcinoma. ORL 59: 106-114, 1997.
14. Maass JD, Hoffmann-Fazel A, Görögh T, Hoffmann M, Meyer JE, Gottschlich S, Rudert H and Maune S: Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer. Anticancer Res 20: 2241-2244, 2000.
15. Molina R, Agusti C, Filella X, Jo J, Joseph J, Gimenez N and Ballesta A: Study of a new tumor marker, Cyfra 21-1, in malignant and nonmalignant diseases. Tumor Biol 15: 318-325, 1994.
16. Pastor A, Menendez R, Cremades MJ, Pastor V, Llopis R and Aznar J: Diagnostic value of SCC, CEA and Cyfra 21-1 in lung cancer: a Bayesian analysis. Eur Respir J 10: 603-609, 1997.
17. Pavicevic R, Milicic J, Bubanovic G and Supe S: Serum tumor marker Cyfra 21-1 in the diagnostics of NSC lung cancer. Coll Antropol 22: 629-635, 1998.
18. Brockmann JG, St Nottberg H, Glodny B, Sprakel B and Senninger N: Analysis of serum Cyfra 21-1 concentrations in patients with esophageal cancer. Anticancer Res 20: 4899-4904, 2000.
19. Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H and Hirakawa K: Serum Cyfra 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89: 1285-1290, 2000.
20. Lin WY, Yen TC, Cheng KY and Wang SJ: The value of Cyfra 21-1, a new tumor marker, in nasopharyngeal carcinoma. Neoplasma 45: 21-24, 1998.
21. Callet N, Cohen-Solal Le Nir CC, Berthelot E and Pichon MF: Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21-1 determinations. Eur J Gynaecol Oncol 19: 50-56, 1998.
22. Doweck I, Barak M, Uri N and Greenberg E: The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 83: 1696-1701, 2000.
23. Niemann AM, Paulsen JI, Lippert BM, Henze E, Görögh T, Gottschlich S and Werner JA: Cyfra 21-1 in patients with head and neck cancer. In: JA Werner, BM Lippert, HH Rudert (Eds.) Head and neck cancer: Advances in basic research. Elsevier, Amsterdam: 529-537, 1996.
24. Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P and Fateh-Moghadam A: Cyfra 21-1 is not superior to SCC-antigen and CEA in head and neck squamous cell cancer. Anticancer Res 16: 3117-3124, 1996.
25. Banal A, Hacence K, Berthelot-Ruff E, Mahe E, Fontana X and Pichon MF: Comparison of Cyfra 21-1 and SCC assays in head and neck tumours. Tumour Biol 22: 27-35, 2001.